These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 606423)

  • 1. Bone histomorphometry in patients with chronic renal failure: effect of 1alpha-hydroxyvitamin D3.
    Melsen F; Nielsen HE; Christensen MS
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():39s-44s. PubMed ID: 606423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3.
    Peacock M; Aaron JE; Walker GS; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428
    [No Abstract]   [Full Text] [Related]  

  • 3. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.
    Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of whole body calcium in chronic renal failure: effects of 1alpha-hydroxyvitamin D3 and parathyroidectomy.
    Naik RB; Dabek JT; Heynen G; James HM; Kanis JA; Robertson PW; Robinson BH; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():139s-145s. PubMed ID: 564247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iliac bone marrow mast cells in relation to the renal osteodystrophy of patients treated by haemodialysis.
    Ellis HA; Peart KM
    J Clin Pathol; 1976 Jun; 29(6):502-16. PubMed ID: 939806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
    Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
    Walker GS; Peacock M; Aaron J; Robinson PJ; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():125s-130s. PubMed ID: 606410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of histological evidence of vitamin D abnormality in the bones of anephric patients.
    Bordier PJ; Chot ST; Eastwood JB; Fournier A; de Wardener HE
    Clin Sci; 1973 Jan; 44(1):33-41. PubMed ID: 4684304
    [No Abstract]   [Full Text] [Related]  

  • 9. [Quantitiative study of iliac bone biopsy in 79 patients with chronic renal failure. Rarity of osteomalacia].
    Latorzeff S; Durand D; Durroux R; Tonthat H; Arlet J; Suc JM
    J Urol Nephrol (Paris); 1976; 82(4-5):329-35. PubMed ID: 940177
    [No Abstract]   [Full Text] [Related]  

  • 10. Vitamin D resistant hypophosphataemic osteomalacia: treatment with 1alpha-hydroxyvitamin D3.
    Peacock M; Heyburn PJ; Aaron JE
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():231s-237s. PubMed ID: 203418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone disease in children with chronic renal failure: therapy with 1alpha-hydroxyvitamin D3.
    Postlethwaite RJ; Houston IB
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():117s-124s. PubMed ID: 304772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease.
    Kanis JA; Earnshaw M; Henderson RG; Heynen G; Ledingham JG; Naik RB; Oliver DO; Russell RG; Smith R; Wilkinson RH; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():45s-50s. PubMed ID: 606424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
    Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 1alpha-hydroxyvitamin D3 on parathyroid function in patients with chronic renal failure.
    Nielsen HE; Christensen MS; Melsen F; Rømer FK; Hansen HE
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():67s-72s. PubMed ID: 606427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of haemodialysis on bone in chronic renal failure.
    Bishop MC; Woods CG; Oliver DO; Ledingham JG; Smith R; Tibbutt DA
    Br Med J; 1972 Sep; 3(5828):664-7. PubMed ID: 4650845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency.
    Pietrek J; Kokot F; Kuska J
    Int Urol Nephrol; 1978; 10(2):153-60. PubMed ID: 700946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopathy in maintenance hemodialysis.
    Krempien B; Ritz E; Beck U; Keilbach H
    Virchows Arch A Pathol Pathol Anat; 1972; 357(4):257-74. PubMed ID: 4629286
    [No Abstract]   [Full Text] [Related]  

  • 19. [The general principles of the diagnosis of dialysis osteomalacia by the results of the histomorphometry of spongy bone].
    Novikov AI; Ivanov AE; Golovniak IE; Baeva LB; Levitskiĭ ER
    Ter Arkh; 1991; 63(12):107-10. PubMed ID: 1803585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.
    Brickman AS; Sherrard DJ; Jowsey J; Singer FR; Baylink DJ; Maloney N; Massry SG; Norman AW; Coburn JW
    Arch Intern Med; 1974 Nov; 134(5):883-8. PubMed ID: 4613310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.